Dual mechanism: Epigenetic inhibitor apabetalone reduces SARS-CoV-2 Delta and Omicron variant spike binding and attenuates SARS-CoV-2 RNA induced inflammation
International Immunopharmacology · 2023
DOI: 10.1016/j.intimp.2023.109929 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2023. Verfasst von Li Fu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Resverlogix Corporation, Calgary, AB, Canada. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
The SARS-CoV-2 virus initiates infection via interactions between the viral spike protein and the ACE2 receptors on host cells. Variants of concern have mutations in the spike protein that enhance ACE2 binding affinity, leading to increased virulence and transmission. Viral RNAs released after entry into host cells trigger interferon-I (IFN-I) mediated inflammatory responses for viral clearance and resolution of infection. However, overreactive host IFN-I responses and pro-inflammatory signals drive COVID-19 pathophysiology and disease severity during acute infection. These immune abnormalities also lead to the development of post-COVID syndrome if persistent. Novel therapeutics are urgently required to reduce short- and long-term pathologic consequences associated with SARS-CoV-2 infection. Apabetalone, an inhibitor of epigenetic regulators of the BET protein family, is a candidate for COVID-19 treatment via a dual mechanism of action. In vitro, apabetalone downregulates ACE2 gene expression to limit SARS-CoV-2 entry and propagation. In pre-clinical models and patients treated for cardiovascular disease, apabetalone inhibits expression of inflammatory mediators involved in the pathologic cytokine storm (CS) stimulated by various cytokines. Here we show apabetalone treatment of human lung epithelial cells reduces binding of viral spike protein regardless of mutations found in the highly contagious Delta variant and heavily mutated Omicron. Additionally, we demonstrate that apabetalone counters expression of pro-inflammatory factors with roles in CS and IFN-I signaling in lung cells stimulated with SARS-CoV-2 RNA. Our results support clinical evaluation of apabetalone to treat COVID-19 and post-COVID syndrome regardless of the SARS-CoV-2 variant.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Resverlogix Corporation, Calgary, AB, Canada.
- Resverlogix Corporation, Calgary, AB, Canada. Electronic address: ewelina@resverlogix.com.
Zitieren
APA
Fu, L., Gilham, D., Stotz, S. C., Sarsons, C. D., Rakai, B. D., Tsujikawa, L. M., Wasiak, S., Johansson, J. O., Sweeney, M., Wong, N. C. W., & Kulikowski, E. (2023). Dual mechanism: Epigenetic inhibitor apabetalone reduces SARS-CoV-2 Delta and Omicron variant spike binding and attenuates SARS-CoV-2 RNA induced inflammation. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2023.109929
Vancouver
Fu L, Gilham D, Stotz SC, Sarsons CD, Rakai BD, Tsujikawa LM, et al. Dual mechanism: Epigenetic inhibitor apabetalone reduces SARS-CoV-2 Delta and Omicron variant spike binding and attenuates SARS-CoV-2 RNA induced inflammation. International Immunopharmacology. 2023. doi:10.1016/j.intimp.2023.109929
BibTeX
@article{Fu2023,
author = {Fu, Li and Gilham, Dean and Stotz, Stephanie C and Sarsons, Christopher D and Rakai, Brooke D and Tsujikawa, Laura M and Wasiak, Sylwia and Johansson, Jan O and Sweeney, Michael and Wong, Norman C W and Kulikowski, Ewelina},
title = {Dual mechanism: Epigenetic inhibitor apabetalone reduces SARS-CoV-2 Delta and Omicron variant spike binding and attenuates SARS-CoV-2 RNA induced inflammation},
journal = {International Immunopharmacology},
year = {2023},
doi = {10.1016/j.intimp.2023.109929}
}
EUVIMED